New drugs from Abbvie, Gilead, Intercept and Merck forecast to achieve blockbuster status by 2020
Annual ‘Drugs to Watch’ study spotlights seven emerging blockbusters poised to enter the market in 2016.
According to a new report from the Intellectual Property & Science business of Thomson Reuters, there are a total of seven new therapeutics currently in the new drug development pipeline that should enter the market this year and surpass $1 billion in annual sales by 2020. Two of these are projected to top $2 billion in annual sales.
These projections are detailed in the annual Drugs to Watch 2016 report, which mines pharmaceutical industry data to forecast the new therapeutics with the largest marketplace potential.
The two new drugs projected to exceed $2 billion in annual sales are a chronic liver disease treatment from Intercept Pharmaceuticals and Sumitomo Dainippon Pharma with the chemical name obeticholic acid II) and an anti-HIV-1 infection treatment from Gilead Sciences and Japan Tobacco which combines the chemicals emtricitabine and tenofovir alafenamide. A key trend in 2016 is the continued development of more convenient fixed-dose, all-oral regimens for HIV and HCV (Hepatitis C).
“The relationship between drug prices and the costs of development is expected to be a major focal point for drug companies, investors, regulators and politicians this year,” said Richard Harrison, Chief Scientific Officer, Intellectual Property & Science, Thomson Reuters. “With the rise of global healthcare costs, the need to demonstrate meaningful impact will be greater than ever for pharmaceutical companies. These seven drugs are likely to figure prominently in those discussions.”
Having accurately anticipated that 11 new potential blockbuster drugs would enter the market in 2015 - all of which are still forecast to reach blockbuster status by 2019 (with the exception of Gardasil 9, for which forecasts were not available as of January 2016) - the Drugs to Watch report addresses a new line-up of significant therapeutics for the year ahead.
Thomson Reuters analysts utilized Cortellis Competitive Intelligence, the pharmaceutical industry’s leading source for drug pipeline, deals, patents, and company content to forecast the new-to-market drugs expected to lead the pack in sales and potentially emerge as blockbusters (earning $ 1 billion+) by 2020.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance